Industry partners

What are the benefits of FinnGen and Finland for our industry partners? This autumn we took the opportunity to interview some representatives of our pharmaceutical partners who wanted to share their experiences of FinnGen.

Access to FinnGen’s unique combination of longitudinal phenotypic and genome data has attracted researchers from the pharmaceutical industry and several international companies have decided to partner with us.

Watch these short interviews to hear why!

Heiko Runz, Biogen

Caroline Fox, Merck

Mark McCarthy, Genentech

Meg Ehm, GSK

FinnGen in brief

FinnGen is a large public-private partnership aiming to collect and analyse genome and health data from 500,000 Finnish biobank participants. FinnGen aims on one hand to provide novel medically and therapeutically relevant insights but also construct a world-class resource that can be applied for future studies.

FinnGen is one of the very first personalized medicine projects at this scale and the public-private collaborative nature of the project is exceptional compared to many ongoing studies. FinnGen brings together Finnish universities, hospitals and hospital districts, THL, Blood Service, biobanks, FINBB and international pharmaceutical companies and hundreds of thousands of Finns. Because collaboration is the key to achieving breakthroughs in disease prevention, diagnosis, and treatment, we welcome everyone on this journey into our shared heritage.